AZD-1940 is a drug developed by
AstraZeneca, that is a peripherally selective
cannabinoid agonist
An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...
which binds with high affinity to both the CB
1 and CB
2 receptors. It was developed for the treatment of
neuropathic pain, but while it showed good peripheral selectivity in animal studies, in human
clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietar ...
s it failed to show sufficient analgesic efficacy and produced unexpectedly strong side effects associated with central cannabinoid activity, and so was discontinued from further development.
See also
*
AZ-11713908
AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB1 receptor and a partial agonist at CB2. It has poor blood–brain barrier penetration, and so while it ...
*
2F-QMPSB
2F-QMPSB (SGT-13) is an arylsulfonamide-based synthetic cannabinoid that is a fluorinated derivative of QMPSB and has been sold as a designer drug. Its identification was first reported by a forensic laboratory in Italy in January 2019, and it wa ...
*
RQ-00202730
RQ-00202730 is a benzimidazole derived drug that acts as a potent and highly selective agonist for the CB2 cannabinoid receptor, with a Ki value of 19nM at CB2 and more than 4000x selectivity over CB1, though it also shows some activity as an an ...
References
Cannabinoids
Benzimidazoles
Tert-butyl compounds
Sulfonamides
Peripherally selective drugs
Experimental drugs
{{cannabinoid-stub